ERBB2 and cancer: The development of dual inhibitors such as 2‐mercaptobenzoxazole derivatives, which target EGFR, HER2, VEGFR2, and CDK2, exemplifies the growing trend toward multitargeted cancer therapies designed to overcome a range of resistance mechanisms [55].